All In Biotech

Drug Trial Radar · NCT07548632

A Clinical Study Evaluating Licaminlimab for Dry Eye Disease

A Phase 2b/3, Double-masked, Randomized, Vehicle-controlled, Multicenter Study Evaluating Licaminlimab in Dry Eye Disease Patients With a Specific TNFR1 Genotype

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Apr 16, 2026

Primary completion

Dec 2026

Study completion Dec 2026

Sponsor

Lead sponsor
OculisIndustry
Sponsor type
Industry
First posted
Apr 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy and safety of the topical ophthalmic administration of licaminlimab as compared to vehicle in participants with Dry Eye Disease and a specific genotype.

Conditions

  • Dry Eye Disease (DED)

Interventions

  • Artificial Tear Run-inOther

    Artificial tear eye drop run-in three times daily (TID) for approximately 14 days.

  • licaminlimabDrug

    Licaminlimab eye drops three times daily (TID) for 29 days.

  • Vehicle of licaminlimabOther

    Inert ophthalmic solution vehicle of licaminlimab, three times daily (TID) for 29 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in global ocular discomfort severity score at Day 29 in participants with DED and specific TNFR1 genotypeTime frame: From Day 1 to Day 29

Locations

14 sites in 1 country. Site status is shown where the registry gives one.

  • East West Eye Institute

    Aliso Viejo, California

  • Orange County Ophthalmology

    Garden Grove, California

  • Global Research Management

    Glendale, California

  • LoBue Laser and Eye Medical Center

    Murrieta, California

  • Eye Research Foundation

    Newport Beach, California

  • North Bay Eye Associates, Inc.

    Petaluma, California

  • Vision Institute

    Colorado Springs, Colorado

  • Segal Drug Trials, Inc.

    Delray Beach, Florida

  • Oculus Research, Inc.

    Garner, North Carolina

  • CORE, Inc

    Shelby, North Carolina

  • Scott & Christie and Associates

    Cranberry Township, Pennsylvania

  • Erie Retina Research

    Erie, Pennsylvania

  • Total Eye Care, PA

    Memphis, Tennessee

  • Piedmont Eye Center, Inc.

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.